bioAffinity Technologies (BIAF) Stock Price

bioAffinity Technologies Price

NYSE·CLOSED
0.53USD-0.03 (-4.78 %)
Market closed

bioAffinity Technologies's net margin stands at -96.6%, up from -313.4% several years earlier. Analysts set a median price target of 6.12 USD, implying 1,056.2% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

bioAffinity Technologies stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of bioAffinity Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how bioAffinity Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing bioAffinity Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

bioAffinity Technologies Stock Price History
DatebioAffinity Technologies Price
8/5/20260.53 USD
8/4/20260.56 USD
8/3/20260.60 USD
7/31/20260.63 USD
7/30/20260.64 USD
7/29/20260.62 USD
7/27/20260.67 USD
7/23/20260.67 USD
7/22/20260.71 USD
7/21/20260.70 USD
7/20/20260.70 USD
7/17/20260.70 USD
7/16/20260.71 USD
7/15/20260.72 USD
7/14/20260.71 USD
7/13/20260.70 USD
7/10/20260.77 USD
7/9/20260.78 USD
7/8/20260.75 USD
7/7/20260.83 USD
7/6/20260.81 USD
7/2/20260.83 USD
7/1/20260.84 USD
6/30/20260.81 USD
6/29/20260.80 USD
6/26/20260.83 USD
6/25/20260.84 USD
6/24/20260.85 USD
6/23/20260.84 USD
6/22/20260.82 USD
6/18/20260.84 USD
6/17/20260.83 USD
6/16/20260.94 USD
6/15/20261.37 USD
6/12/20261.48 USD
6/11/20261.63 USD
6/10/20261.52 USD
6/9/20261.51 USD
6/8/20261.60 USD
6/5/20261.73 USD
6/4/20261.88 USD
6/3/20261.69 USD
6/2/20261.68 USD
6/1/20261.75 USD
5/29/20261.67 USD
5/28/20261.65 USD
5/27/20261.65 USD
5/26/20261.65 USD
5/22/20261.56 USD
5/21/20261.62 USD
5/20/20261.66 USD
5/19/20261.70 USD
5/18/20261.68 USD
5/15/20261.88 USD
5/14/20261.96 USD
5/13/20261.89 USD
5/12/20261.88 USD
5/11/20261.97 USD
5/8/20262.03 USD
5/7/20262.12 USD
5/5/20262.02 USD
5/4/20262.18 USD
5/1/20262.19 USD
4/30/20262.48 USD
4/29/20262.43 USD
4/28/20262.66 USD
4/27/20262.21 USD
4/24/20262.23 USD
4/23/20262.30 USD
4/22/20262.51 USD
4/21/20262.61 USD
4/20/20262.69 USD
4/17/20262.86 USD
4/16/20262.76 USD
4/15/20262.93 USD
4/14/20262.81 USD
4/13/20263.18 USD
4/10/20263.35 USD
4/9/20263.32 USD
4/8/20263.92 USD
4/7/20264.09 USD
4/6/20264.18 USD
4/2/20263.92 USD
4/1/20263.98 USD
3/31/20263.83 USD
3/30/20263.54 USD
3/27/20264.00 USD
3/26/20264.74 USD
3/25/20263.97 USD
3/24/20263.96 USD
3/23/20264.73 USD
3/20/20262.73 USD
3/19/20262.97 USD
3/18/20262.43 USD
3/17/20262.74 USD
3/16/20261.91 USD
3/13/20262.12 USD
3/12/20261.07 USD
3/11/20261.13 USD
3/10/20261.19 USD
3/9/20261.06 USD
3/6/20261.04 USD
3/5/20261.03 USD
3/4/20261.03 USD
3/3/20260.95 USD
3/2/20261.06 USD
2/27/20261.06 USD
2/26/20261.04 USD
2/25/20261.09 USD
2/24/20261.11 USD
2/23/20260.93 USD
2/20/20261.08 USD
2/19/20261.18 USD
2/18/20261.15 USD
2/17/20261.07 USD
2/13/20261.04 USD
2/12/20261.10 USD
2/11/20260.99 USD
2/10/20261.01 USD
2/9/20260.90 USD
2/6/20260.85 USD
2/5/20260.75 USD
2/4/20260.86 USD
2/3/20261.07 USD
2/2/20261.27 USD
1/30/20261.14 USD
1/29/20261.17 USD
1/28/20261.26 USD
1/27/20261.32 USD
1/26/20261.30 USD
1/23/20261.35 USD
1/22/20261.36 USD
1/21/20261.31 USD
1/20/20261.31 USD
1/16/20261.37 USD
1/15/20261.42 USD
1/14/20261.26 USD
1/13/20261.25 USD
1/12/20261.27 USD
1/9/20261.33 USD
1/8/20261.29 USD
1/7/20261.29 USD
1/6/20261.29 USD
1/5/20261.25 USD
1/2/20261.22 USD
12/31/20251.18 USD
12/30/20251.23 USD
12/29/20251.17 USD
12/26/20251.17 USD
12/24/20251.23 USD
12/23/20251.23 USD
12/22/20251.27 USD
12/19/20251.24 USD
12/18/20251.22 USD
12/17/20251.29 USD
12/16/20251.38 USD
12/15/20251.48 USD
12/12/20251.51 USD
12/11/20251.66 USD
12/10/20251.69 USD
12/9/20251.66 USD
12/8/20251.65 USD
12/5/20251.63 USD
12/4/20251.72 USD
12/3/20251.57 USD
12/2/20251.43 USD
12/1/20251.37 USD
11/28/20251.50 USD
11/26/20251.45 USD
11/25/20251.43 USD
11/24/20251.43 USD
11/21/20251.47 USD
11/20/20251.38 USD
11/19/20251.47 USD
11/18/20251.47 USD
11/17/20251.58 USD
11/14/20251.84 USD
11/13/20251.88 USD
11/12/20252.15 USD
11/11/20252.16 USD
11/10/20252.09 USD
11/7/20252.06 USD
11/6/20252.05 USD
11/5/20252.17 USD
11/4/20252.09 USD
11/3/20252.30 USD
10/31/20252.45 USD
10/30/20252.44 USD
10/29/20252.48 USD
10/28/20252.49 USD
10/27/20252.59 USD
10/24/20252.65 USD
10/23/20252.64 USD
10/22/20252.52 USD
10/21/20252.83 USD
10/20/20252.88 USD
10/17/20252.94 USD
10/16/20253.41 USD
10/15/20252.71 USD
10/14/20252.88 USD
10/13/20252.66 USD
10/10/20252.72 USD
10/9/20252.90 USD
10/8/20253.05 USD
10/7/20252.45 USD
10/6/20252.56 USD
10/3/20252.61 USD
10/2/20252.78 USD
10/1/20252.90 USD
9/30/20252.96 USD
9/29/20253.25 USD
9/26/20253.25 USD
9/25/20252.09 USD
9/24/20252.64 USD
9/23/20252.99 USD
9/22/20253.18 USD
9/19/20253.06 USD
9/18/20253.11 USD
9/17/20253.37 USD
9/16/20254.81 USD
9/15/20256.45 USD
9/12/20254.98 USD
9/11/20254.70 USD
9/10/20254.72 USD
9/9/20254.57 USD
9/8/20254.52 USD
9/5/20254.41 USD
9/4/20254.41 USD
9/3/20254.55 USD
9/2/20254.37 USD
8/29/20254.46 USD
8/28/20254.52 USD
8/27/20254.57 USD
8/26/20254.64 USD
8/25/20254.59 USD
8/22/20254.68 USD
8/21/20254.59 USD
8/20/20254.59 USD
8/19/20254.92 USD
8/18/20254.52 USD
8/15/20254.29 USD
8/14/20254.70 USD
8/13/20255.16 USD
8/12/20255.05 USD
8/11/20255.14 USD
8/8/20255.31 USD
Access this data via the Eulerpool API
Get Free API Key

bioAffinity Technologies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
0.00 USD
-2.60 M USD
-7.27 M USD
Jan 1, 2021
0.00 USD
-2.21 M USD
-6.33 M USD
Jan 1, 2022
0.00 USD
-4.01 M USD
-8.15 M USD
Jan 1, 2023
2.53 M USD
-7.97 M USD
-7.94 M USD
Jan 1, 2024
9.36 M USD
-8.95 M USD
-9.04 M USD
Jan 1, 2025 (e)
6.21 M USD
-11.01 M USD
-66.10 M USD
Jan 1, 2026 (e)
7.45 M USD
-11.29 M USD
-37.18 M USD

bioAffinity Technologies Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 12:06 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESk
202020212022202320242025e2026e
–––2.009.006.007.00
––––350.00-33.3316.67
–––150.0033.3333.3333.33
3.003.003.003.003.002.002.33
-2.00-2.00-4.00-7.00-8.00-11.00-11.00
–––-350.00-88.89-183.33-157.14
-7.00-6.00-8.00-7.00-9.00-66.00-37.00
–-14.2933.33-12.5028.57633.33-43.94
90.9090.90150.00291.50404.10404.10404.10
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales bioAffinity Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue bioAffinity Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare bioAffinity Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares bioAffinity Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against bioAffinity Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

bioAffinity Technologies stock margins

The bioAffinity Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of bioAffinity Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for bioAffinity Technologies.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
36.09 %
- %
- %
Jan 1, 2021
36.09 %
- %
- %
Jan 1, 2022
36.09 %
- %
- %
Jan 1, 2023
31.26 %
-314.84 %
-313.41 %
Jan 1, 2024
36.09 %
-95.64 %
-96.56 %
Jan 1, 2025 (e)
36.09 %
-177.29 %
-1,064.52 %
Jan 1, 2026 (e)
36.09 %
-151.42 %
-498.85 %

bioAffinity Technologies Stock Revenue, EBIT, Earnings per Share

The bioAffinity Technologies earnings per share therefore indicates how much revenue bioAffinity Technologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 USD
-858.09 USD
-2,399.34 USD
Jan 1, 2021
0.00 USD
-729.37 USD
-2,089.11 USD
Jan 1, 2022
0.00 USD
-802.00 USD
-1,630.00 USD
Jan 1, 2023
260.63 USD
-820.57 USD
-816.84 USD
Jan 1, 2024
695.03 USD
-664.70 USD
-671.11 USD
Jan 1, 2025 (e)
41.39 USD
-817.21 USD
-440.64 USD
Jan 1, 2026 (e)
49.69 USD
-837.81 USD
-247.86 USD

bioAffinity Technologies business model & stock analysis

bioAffinity Technologies Segments

bioAffinity Technologies Revenue by Segment (1/3)

  • Max

Histology Service Fees
Health Care, Patient Service
Histology Fees
Medical Director Fees
Health Care, Other
Other Revenues
Department of Defense Observational Studies
Details
Date
Histology Service Fees
Health Care, Patient Service
Histology Fees
Medical Director Fees
Health Care, Other
Other Revenues
Department of Defense Observational Studies
Jan 1, 2023
0.00 USD
2.20 M USD
272,660.00 USD
0.00 USD
19,324.00 USD
21,515.00 USD
19,442.00 USD
Jan 1, 2024
1.10 M USD
516,000.00 USD
0.00 USD
66,576.00 USD
0.00 USD
7,371.00 USD
8,654.00 USD
Jan 1, 2025
1.12 M USD
963,000.00 USD
0.00 USD
68,268.00 USD
0.00 USD
4,860.00 USD
577.00 USD

bioAffinity Technologies Revenue by Segment (2/3)

  • Max

Laboratory Services
Diagnostic R&D
Details
Date
Laboratory Services
Diagnostic R&D
Jan 1, 2023
2.51 M USD
19,442.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD

bioAffinity Technologies Revenue by Segment (3/3)

  • Max

Laboratory Services
Diagnostic R&D
Diagnostic Research And Development
Details
Date
Laboratory Services
Diagnostic R&D
Diagnostic Research And Development
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
9.35 M USD
8,654.00 USD
0.00 USD
Jan 1, 2025
6.16 M USD
0.00 USD
577.00 USD

bioAffinity Technologies Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

bioAffinity Technologies historical P/E ratio, EBIT multiple, and P/S ratio

bioAffinity Technologies annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

bioAffinity Technologies shares outstanding

The number of shares of bioAffinity Technologies was 13,470 in 2025. This indicates how many shares bioAffinity Technologies is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
3,030.00 Stocks
Jan 1, 2021
3,030.00 Stocks
Jan 1, 2022
5,000.00 Stocks
Jan 1, 2023
9,716.67 Stocks
Jan 1, 2024
13,470.00 Stocks
Jan 1, 2025 (e)
13,470.00 Stocks
Jan 1, 2026 (e)
13,470.00 Stocks

bioAffinity Technologies stock splits

In bioAffinity Technologies's history, there have been no stock splits.

Current bioAffinity Technologies forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
6.12
Last Price
0.53
Currency
USD
12M Return Potential
1,056.24 %
LTM Return
0 %

bioAffinity Technologies Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/19/2026-2.14USD-1.74 MUSD-2026 Q2
5/20/2026-2.45USD-1.51 MUSD-2026 Q1
4/6/2026-2.75USD-1.58 MUSD-2025 Q4
11/14/2025-2.75USD-1.44 MUSD-2025 Q3
8/12/2025-0.10USD-1.54 MUSD-2025 Q2
11/11/2024-0.15USD-2.59 MUSD-2024 Q3

bioAffinity Technologies shareholder structure

% Name
1.30404%
District 2 Capital LP
District 2 Capital LP
1.30404%
Bigger Capital Funds, LP
Bigger Capital Funds, LP
0.80656%
Girgenti (Steven)
Girgenti (Steven)
0.67604%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
0.45009%
The Joyce Living Trust
The Joyce Living Trust
0.28278%
Northern Trust Investments, Inc.
Northern Trust Investments, Inc.

bioAffinity Technologies Executives and Management Board

14 members · avg. age 70 · 14 % women

MZ

Ms. Maria Zannes (69)

President, Chief Executive Officer, Director · since 2014

477,155.00 USD

Management

JE

Mr. James Edwards (58)

Chief Financial Officer · since 2024

273,213.00 USD
XR

Mr. Xavier Reveles (56)

Chief Operating Officer

–
TZ

Mr. Timothy Zannes (72)

Executive Vice President, General Counsel, Secretary

–
WB

Dr. William Bauta

Chief Science Officer

–
GD

Mr. Gordon Downie

Chief Medical Officer

–

Board of Directors

RJ

Dr. Roby Joyce (77)

Director

611,905.00 USD
SG

Mr. Steven Girgenti (79)

Executive Chairman of the Board · since 2014

306,679.00 USD
PK

Mr. Peter Knight (74)

Independent Director

139,998.00 USD
JP

Dr. Jamie Platt (58)

Independent Director

139,373.00 USD
RA

Mr. Robert Anderson (84)

Independent Director

137,498.00 USD
JO

Dr. John Oppenheimer

Director

–

Frequently asked questions about bioAffinity Technologies

Analysts currently set an average price target of 6.12 USD for the bioAffinity Technologies stock (median: 6.12 USD), implying +1,056.2 % versus the latest price. The consensus is based on 7 analyst ratings.

bioAffinity Technologies Analyst Price Targets 2026

6 analysts currently rate the bioAffinity Technologies stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect bioAffinity Technologies to generate revenue of 7.45 M USD and earnings per share of -2,760.13 USD.

bioAffinity Technologies Analyst Price Targets 2026

Converted at the current exchange rate, the bioAffinity Technologies share trades at 0.46 EUR (0.53 USD).

No history available for bioAffinity Technologies.

The expected revenue of bioAffinity Technologies is 7.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of bioAffinity Technologies is -37.18 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of bioAffinity Technologies is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the bioAffinity Technologies stock.

The price-to-sales ratio (P/S) of bioAffinity Technologies is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the bioAffinity Technologies stock.

The Eulerpool Quality Score for bioAffinity Technologies is 3/10.

The ISIN of bioAffinity Technologies is US09076W3079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of bioAffinity Technologies is BIAF. The ticker symbol is used to trade bioAffinity Technologies shares on the stock exchange.

bioAffinity Technologies paid dividends every year for the past 0 years.

bioAffinity Technologies is assigned to the 'Health' sector.

The dividends of bioAffinity Technologies are distributed in USD.

All fundamentals and in-depth analysis of bioAffinity Technologies

Our stock analysis for bioAffinity Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of bioAffinity Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

bioAffinity Technologies Stock
bioAffinity Technologies Revenue→
bioAffinity Technologies Stock
bioAffinity Technologies Net Income→
bioAffinity Technologies Stock
bioAffinity Technologies P/E→
bioAffinity Technologies Stock
bioAffinity Technologies P/S→
bioAffinity Technologies Stock
bioAffinity Technologies EBIT→
bioAffinity Technologies Stock
bioAffinity Technologies Dividend→
bioAffinity Technologies Stock
bioAffinity Technologies Directors Dealings→
bioAffinity Technologies Stock
bioAffinity Technologies Stocks→
bioAffinity Technologies Stock
bioAffinity Technologies Market capitalization→
bioAffinity Technologies Stock
bioAffinity Technologies Debt→
bioAffinity Technologies Stock
bioAffinity Technologies Liabilities→
bioAffinity Technologies Stock
bioAffinity Technologies Equity→
bioAffinity Technologies Stock
bioAffinity Technologies AAQS→
bioAffinity Technologies Stock
bioAffinity Technologies Employees→
bioAffinity Technologies Stock
bioAffinity Technologies ROE→
bioAffinity Technologies Stock
bioAffinity Technologies ROA→
bioAffinity Technologies Stock
bioAffinity Technologies ROCE→
bioAffinity Technologies Stock
bioAffinity Technologies News→
bioAffinity Technologies Stock
bioAffinity Technologies Analyst Price Targets→

Health Stocks

BIOAGE LabsBio-Works TechnologiesBioArcticBio-Thera SolutionsBioatlaBio-TechneBiobijou CoBio-FD&C CoBioCardiaBio ViewBioceltixBio Solution CoAll Stocks A–Z →